home / stock / glpgf / glpgf quote
Last: | $22.60 |
---|---|
Change Percent: | 0.0% |
Open: | $22.6 |
Close: | $22.60 |
High: | $22.6 |
Low: | $22.6 |
Volume: | 12 |
Last Trade Date Time: | 06/21/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$22.6 | $22.6 | $22.6 | $22.6 | $22.6 | 12 | 06-21-2024 |
$26.2 | $26.2 | $26.2 | $26.2 | $26.2 | 190 | 04-17-2024 |
$35.5157 | $0 | $35.5157 | $0 | $0 | 47,000 | 04-10-2024 |
$35.5157 | $0 | $35.5157 | $0 | $0 | 12,600 | 03-27-2024 |
$35.5157 | $35.5157 | $35.5157 | $35.5157 | $35.5157 | 4,812 | 02-29-2024 |
$36.2 | $36.2 | $36.2 | $36.2 | $36.2 | 30 | 02-09-2024 |
$36.21 | $36.21 | $36.21 | $36.21 | $36.21 | 2 | 02-06-2024 |
$33.82 | $0 | $33.82 | $0 | $0 | 70,000 | 02-01-2024 |
$33.82 | $0 | $33.82 | $0 | $0 | 40,000 | 01-22-2024 |
$33.82 | $33.82 | $33.82 | $33.82 | $33.82 | 5,000 | 11-13-2023 |
$30.1 | $30.1 | $30.1 | $30.1 | $30.1 | 75 | 10-25-2023 |
$37.25 | $37.25 | $37.25 | $37.25 | $37.25 | 81 | 08-25-2023 |
$34.9 | $34.9 | $34.9 | $34.9 | $34.9 | 39 | 08-23-2023 |
$39 | $39 | $39 | $39 | $39 | 7 | 08-21-2023 |
$38 | $38 | $38 | $38 | $38 | 150 | 08-08-2023 |
$41.75 | $41.7 | $41.75 | $41.75 | $41.7 | 150 | 07-26-2023 |
$41.6 | $0 | $41.6 | $0 | $0 | 35 | 07-12-2023 |
$41.6 | $41.6 | $41.6 | $41.6 | $41.6 | 5,000 | 06-20-2023 |
$38 | $38 | $38 | $38 | $38 | 50 | 04-26-2023 |
$37.5 | $37.5 | $37.5 | $37.5 | $37.5 | 50 | 04-05-2023 |
News, Short Squeeze, Breakout and More Instantly...
Galapagos Genomics Ord Company Name:
GLPGF Stock Symbol:
OTCMKTS Market:
Galapagos Genomics Ord Website:
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual Euro...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown enc...
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access ...